Baxa Corporation Introduces the InFuse(TM) T-10 Syringe Infuser

ENGLEWOOD, Colo., May 24 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release of the InFuse T-10 Syringe Infuser.  Specifically designed for the delivery of intermittent antibiotics and other non-rate critical intravenous doses, the Baxa InFuse T-10 Syringe Infuser frees up expensive, smart infusion pumps for more critical applications and gives nurses more time to focus on patient care.

As hospitals and healthcare systems continue to evaluate ways to reduce costs and improve efficiency, the Baxa InFuse T-10 Infuser offers significant cost savings over minibag IV delivery.  When paired with the IntelliFill® i.v. or RapidFill™ Syringe Filling Automation, the InFuse Infuser provides a complete system for easy administration of filled antibiotic syringes.  The result is a medication delivery system at a significantly lower cost than competitive options.  According to a Pharmacy Practice News Special Report titled, "Re-engineering the IV. Medication Delivery System to Reduce Costs and Improve Patient Outcomes," Partners Healthcare realized a first-year savings of $1.4 million upon switching from minibags to a syringe infuser.  Estimated savings using the InFuse Infuser range from $1 to $5 per dose.

Specific benefits of the new Baxa InFuse T-10 simple syringe infuser include:

Ease of use – The InFuse T-10 Infuser accommodates intermittent antibiotic dose deliveries from 0.5 to 10 mL.  Its simple design and operation make it easy to implement with minimal clinical practice changes.  Lightweight, portable and tough, the InFuse T-10 offers silent delivery with no required programming or maintenance.  Its simple design and one-click operation make it easy to implement with minimal clinical practice changes.

Cost Savings – At a list price of $150 each, InFuse Infusers have a low initial cost.  And, their recurring costs are less expensive than programmable infusion pumps.  By taking $1-$2 of cost per dose out of a high-volume health system, significant dollars can be allocated for other important initiatives.

Pharmacy Efficiency – The InFuse T-10 provides a simple solution for administering the large quantities of syringe doses produced through pharmacy automation such as the Baxa IntelliFill i.v. or RapidFill Automated Syringe Filler.

Nursing Resources – Nurses face challenges including staff shortages, increased patient acuity and new compliance regulations.  The InFuse T-10 eliminates the need for nurses to administer IV push medications and allows them to spend more time on patient care.

Patient Outcomes – Syringe delivery with the InFuse T-10 Infuser reduces the fluid volume administered when compared with ready-to-use or minibag delivery.  Fluid restriction contributes to better patient outcomes through fluid balancing – reducing adverse effects on internal organs from fluid overload.

"The Baxa InFuse T-10 is a compact solution that complements the Baxa RapidFill and IntelliFill i.v. syringe filling automation as a simple solution for delivering intermittent antibiotics in standardized syringe-based doses," states Megan Kleckner, Baxa Senior Product Manager.

Lightweight, portable and tough, the InFuse T-10 offers silent delivery with no required programming or maintenance.  Its simple design and one-click operation make it easy to implement with minimal clinical practice changes.

Product Availability

The Baxa InFuse T-10 simple syringe infuser is available immediately.  For more product information, please visit www.baxa.com/infuse, or contact us at [email protected] for a demonstration or quote to meet your facility's needs.

About Baxa Corporation

Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications.  The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies.  Privately held, Baxa Corporation has subsidiaries in Canada and the United Kingdom, sales infrastructure in Austria, Belgium, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide.  Further information is available at www.baxa.com.

SOURCE Baxa Corporation